Genetic testing in children with autism spectrum disorders

Area of Science:

• Genetics
• Pediatrics
• Neurodevelopmental Disorders

Background:

• Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition.
• Identifying genetic factors in ASD is crucial for diagnosis and management.
• The American Academy of Pediatrics Clinical Report guides genetic evaluation in ASD.

Purpose of the Study:

• To investigate karyotype abnormalities, MECP2 mutations, and Fragile X in children with ASD.
• To assess the yield of genetic testing in a clinical ASD population.
• To evaluate factors associated with genetic testing in ASD.

Main Methods:

• Ninety-six children diagnosed with ASD were included in the study.
• Genetic testing, including karyotyping and Fragile X DNA analysis, was performed.
• Factors influencing genetic testing decisions were evaluated.

Main Results:

• Karyotype abnormalities were detected in 9.7% of the children.
• Fragile X (FRAXA) DNA testing was positive in 1.4% of cases.
• Specific karyotype abnormalities included inversions, translocations, and deletions.

Conclusions:

• Genetic testing, including karyotype and FRAXA assessment, should be offered to all families of children with ASD.
• These tests yield positive results in approximately 10% of cases.
• Clinical history, physical examination, and geneticist consultation remain vital for ASD etiological evaluation.